patient
acut
infecti
diseas
develop
fever
frequent
reason
visit
health
facil
resourcelimit
set
symptomat
overlap
febril
diseas
imped
diagnosi
clinic
ground
therefor
world
health
organ
promot
integr
manag
febril
ill
along
line
present
overview
endem
epidem
etiolog
fever
stateoftheart
diagnost
tool
use
field
becom
evid
urgent
need
develop
novel
technolog
fulfil
endus
requir
need
met
pointofcar
nearpati
diagnost
platform
well
ehealth
clinic
algorithm
coassess
test
result
key
clinic
element
biosensor
assist
clinician
patient
triag
manag
thu
enhanc
diseas
surveil
outbreak
alert
review
give
overview
diagnost
technolog
featur
platform
base
approach
assay
nucleic
acid
amplif
technolog
examin
ii
cartridg
microfluid
technolog
present
iii
instrument
variou
detect
technolog
discuss
end
propos
way
technolog
interfac
electron
clinic
decisionmak
algorithm
toward
broad
complet
diagnost
ecosystem
peopl
lowand
middleincom
countri
lmic
primarili
subsaharan
africa
southeast
asia
latin
america
suffer
dramat
infecti
diseas
endem
other
occur
form
epidem
combin
factor
lead
perpetu
situat
includ
tropic
climat
simultan
present
multipl
diseas
innat
acquir
host
factor
micronutri
defici
immunodefici
comorbid
lack
resourc
low
incom
procur
medicin
vaccin
prevent
tool
lackmisus
due
lack
train
inform
suitabl
diagnost
tool
increas
pathogen
resist
antimicrobi
medicin
well
social
commun
factor
result
death
worldwid
still
due
infecti
diseas
pneumonia
malaria
sepsi
lead
caus
death
particularli
africa
moreov
border
tropic
diseas
thought
confin
around
equat
ebola
infecti
diseas
classic
relat
northern
countri
influenza
discret
climat
chang
increas
popul
migrat
contribut
blur
border
thu
make
spread
febril
ill
global
realiti
concern
mani
peopl
acut
infecti
diseas
develop
fever
frequent
complaint
observ
approxim
pediatr
adult
patient
present
acut
medic
condit
health
facil
estim
incid
febril
episod
malaria
endem
countri
vari
accord
studi
gener
episod
per
person
per
year
children
year
despit
fact
infecti
diseas
caus
fever
result
differ
type
pathogen
parasit
virus
bacteriaeach
requir
differ
type
treatment
manag
malaria
major
caus
fever
decad
ago
http
given
still
high
often
increas
number
febril
relat
ill
case
accompani
mortal
global
emerg
global
threat
eg
ebola
increas
resist
antimicrobi
medicin
sever
convent
intern
level
aim
defin
roadmap
tackl
challeng
signific
conclus
decis
deriv
summit
meet
summar
world
health
organ
chang
polici
regard
case
manag
malaria
shift
presumpt
treatment
laboratorybas
confirm
malaria
treatment
thu
wide
access
malaria
diagnosi
advoc
protect
avail
antimalari
medicin
develop
resist
accord
global
report
surveil
antimicrobi
resist
emerg
drug
resist
due
misus
antimicrobi
one
major
current
public
health
threat
worldwid
new
tool
could
mitig
threat
urgent
requir
summari
lesson
learn
ebola
epidem
bill
gate
mention
need
invest
better
diseasesurveil
laboratorytest
capac
normal
situat
epidem
routin
surveil
system
earli
sign
outbreak
beyond
sentinel
site
quickli
scale
epidem
link
nation
public
health
laboratori
enabl
robust
monitor
respons
ebolafocus
summit
conven
paul
allen
foundat
april
one
conclus
state
greatest
unmet
fieldtest
use
commun
villag
help
determin
whether
isol
andor
referr
indic
expert
meet
june
focus
interoper
standard
conclud
clear
need
interfac
system
diagnost
tool
ehealth
technolog
aim
patient
manag
epidem
control
conclus
direct
come
multipl
site
strongli
demonstr
need
motiv
exist
support
develop
new
innov
diagnost
tool
effici
resolv
aforement
challeng
relat
febril
ill
first
step
improv
manag
patient
febril
ill
estim
distribut
variou
syndrom
pathogen
caus
fever
even
though
distribut
fevercaus
diseas
vari
geographi
season
age
immun
patient
level
care
find
similar
among
studi
relat
cosmopolitan
diseas
found
place
worldwid
pneumonia
urinari
tract
infect
diseas
variou
level
endem
typhoid
rickettsiosi
occur
rather
epidem
way
arboviru
infect
preval
vari
significantli
accord
geograph
locat
even
accord
season
calendar
year
studi
record
clinic
present
patient
laboratori
result
caus
fever
outpati
could
classifi
four
main
syndrom
acut
respiratori
infect
ari
type
diarrhea
gastroenter
fever
anoth
clear
focu
eg
mening
skin
infect
nonspecif
fever
diagnost
platform
describ
section
focus
least
one
aforement
case
even
though
import
diagnost
challeng
remain
regard
first
three
syndrom
clear
clinic
guidelin
develop
integr
manag
childhood
ill
imci
help
clinician
assess
patient
decid
treatment
correspond
local
infect
syndrom
gener
diagnos
use
best
avail
clinic
predictor
diagnost
tool
inde
includ
contrast
regard
syndrom
nonspecif
fever
guidelin
avail
main
challeng
face
clinician
manag
patient
fever
without
specif
symptom
sign
guid
sourc
infect
combin
endem
area
neg
malaria
test
result
neg
syndrom
label
health
worker
tanzania
nonspecif
fever
also
call
fever
without
focu
caus
wide
rang
pathogen
fig
tabl
identifi
without
accur
laboratori
test
recent
studi
aim
determin
etiolog
fever
identifi
follow
import
diseas
caus
nonspecif
fever
malaria
continu
major
global
health
problem
accord
world
malaria
report
countri
still
malaria
endem
estim
million
case
malaria
worldwid
estim
death
malaria
death
occur
africa
malaria
preval
vari
wide
fever
inde
decreas
malaria
transmiss
mani
place
africa
led
signific
heterogen
transmiss
preval
malaria
among
patient
febril
ill
therefor
becom
unpredict
trigger
switch
malaria
case
manag
polici
presumpt
treatment
treatment
base
laboratori
confirm
ii
urinari
tract
infect
import
caus
fever
young
children
gener
younger
two
year
old
suspect
basi
histori
urinari
symptom
age
therefor
includ
categori
nonspecif
fever
preval
among
children
five
febril
ill
iii
enter
fever
signific
caus
fever
children
older
two
year
old
adult
account
fever
salmonella
typhi
frequent
pathogen
identifi
follow
salmonella
nontyphi
iv
bloodstream
infect
mainli
due
streptococcu
pneumonia
escherichia
coli
account
fever
system
bacteri
diseas
leptospirosi
rickettsiosi
q
fever
brucellosi
also
import
caus
fever
especi
adult
expos
zoonos
environmentalrel
diseas
children
v
dengu
also
import
caus
seem
emerg
sever
african
countri
preval
extrem
variabl
much
geograph
tempor
season
year
year
variat
vi
cosmopolitan
virus
human
herpesviru
parvoviru
epsteinbarr
viru
cytomegaloviru
transmit
mainli
close
contact
within
famili
member
mostli
preval
children
account
fever
nonspecif
fever
children
adult
suscept
vectorborn
diseas
chikungunya
west
nile
viru
acut
hiv
found
patient
vii
coinfect
two
even
pathogen
frequent
one
studi
pediatr
patient
one
diseas
simultan
fig
especi
outbreak
overlap
endem
situat
happen
fever
studi
tanzania
suddenli
januari
signific
outbreak
dengu
start
peak
epidem
almost
patient
present
fever
infect
dengu
viru
serotyp
absenc
diagnost
tool
outsid
studi
site
patient
consid
malaria
case
treat
antimalari
medicin
case
malaria
test
avail
consid
possibl
infect
bacteria
treat
antibiot
viii
regard
hiv
chronic
hiv
import
comorbid
especi
adult
posit
two
tanzanian
studi
hiv
preval
correspond
commun
thu
systemat
screen
unfortun
case
present
africa
whatev
etiolog
first
step
assess
febril
patient
triag
sever
rather
mild
ill
object
pointofcar
poc
biosensor
oximet
addit
subject
assess
clinic
danger
sign
lethargi
sever
dehydr
help
correctli
triag
patient
integr
evalu
process
patient
present
mild
diseas
ambulatori
manag
appropri
homebas
treatment
suffici
main
challeng
identifi
patient
benefit
antimicrobi
treatment
among
selflimit
infect
presumpt
treatment
antimicrobi
avoid
infect
viral
origin
fig
especi
children
except
malaria
rule
rapid
diagnost
test
followup
patient
detect
persist
new
symptom
sign
allow
detect
rare
clinic
failur
primari
care
level
decis
administ
antimicrobi
base
initi
classif
condit
four
categori
mention
section
combin
accur
test
specif
syndrom
distinguish
bacteri
viral
etiolog
exist
host
biomark
lack
accuraci
exampl
creactiv
protein
identifi
bacteri
pneumonia
case
among
mani
viral
respiratori
infect
combin
clinic
predictor
eg
fast
breath
improv
overal
specif
patient
rather
sever
febril
ill
satisfi
criteria
sepsi
admit
assess
differ
etiolog
fever
irrespect
syndrom
present
sepsi
symptom
sign
inde
often
unspecif
allow
initi
classif
four
syndrom
mention
section
possibl
consid
condit
accur
laboratori
diagnosi
import
infect
list
section
take
account
specif
exposur
mention
patient
local
epidemiolog
test
whenev
possibl
result
laboratori
test
still
interpret
clinic
context
ie
pretest
probabl
diseas
likelihood
ratio
clinic
predictor
inde
laboratori
test
imperfect
accuraci
element
consid
calcul
posttest
probabl
abl
safe
includ
exclud
certain
diseas
probabl
treatment
threshold
one
treat
patient
instead
continu
investig
use
test
appropri
antimicrobi
administ
probabl
diagnost
threshold
specif
treatment
requir
besid
adjunct
treatment
eg
ie
acut
respiratori
infect
gastroenter
skin
infect
mening
nasopharyng
infect
infect
due
enteroviru
adenoviru
influenza
howev
present
without
respiratori
symptom
sourc
figur
provid
v
dacremont
adapt
classif
fevercaus
pathogen
africa
parasit
bacteri
viral
fungal
system
infect
na
applic
unknown
naat
nucleic
acid
amplif
technolog
lft
later
flow
test
diseas
includ
gener
consid
one
week
fever
sinus
viscer
leishmaniasi
amoeb
liver
abscess
diseas
includ
although
fairli
preval
rare
present
fever
pertussi
cryptosporidium
diseas
includ
clinic
diagnosi
gener
sensit
enough
specif
enough
measl
medium
sensit
hiv
patient
low
cell
count
urinari
test
k
mitsakaki
et
al
microelectron
engin
intraven
rehydr
patient
sever
diarrhea
treatment
chronic
condit
probabl
fall
two
threshold
test
avail
may
requir
secondlin
test
use
practic
antimicrobi
often
administ
presumpt
wait
test
result
except
malaria
exclud
min
base
result
rapid
test
summari
evidencebas
integr
manag
fever
complex
process
hospit
primari
care
level
would
clearli
benefit
electron
clinic
decis
algorithm
ecda
base
mobil
technolog
guid
clinician
necessari
step
reach
accur
evalu
diseas
probabl
decid
appropri
treatment
manag
electron
clinic
decis
algorithm
ehealth
tool
pertain
broader
categori
computer
decis
support
system
cdss
contrari
differenti
diagnosi
gener
ddx
provid
long
list
possibl
diagnos
shown
poor
accuraci
ecda
provid
structur
decis
pathway
align
clinician
workflow
guid
clinician
throughout
consult
includ
final
treatment
advic
section
diagnost
tool
target
inand
outpati
visit
urban
rural
hospit
peripher
health
facil
laboratori
commun
level
health
post
particular
follow
broad
categori
target
group
identifi
patient
live
resourcelimit
countri
clearli
need
new
diagnost
test
infecti
diseas
patient
divers
immun
statu
chronic
condit
may
suffer
abil
willing
pay
diagnost
test
ii
peopl
travel
endem
nonendem
area
although
difficult
determin
number
return
travel
migrant
northern
countri
infect
endem
diseas
variat
report
method
differ
pathogen
estim
case
travel
malaria
exampl
report
europ
year
number
peopl
cross
border
southern
countri
much
higher
repres
also
import
target
group
test
airport
harbor
crossbord
control
immigr
control
checkpoint
reliabl
short
timetoresult
test
requir
iii
preand
postvaccin
elimin
screen
program
run
local
govern
intern
organ
pharmaceut
industri
diseas
prevent
elimin
program
support
comprehens
evid
demonstr
underli
preval
pathogen
question
efficaci
strategi
propos
use
multiplexingcap
diagnost
platform
allow
effect
model
true
preval
variat
multipl
speci
enabl
monitor
impact
intervent
diseas
dynam
b
local
region
differ
pathogen
distribut
iv
epidem
surveil
particularli
interest
sentinel
site
diagnost
tool
instal
strateg
geograph
locat
order
cover
sever
region
cultur
environment
epidemiolog
set
b
ministri
health
region
alarm
center
regularli
receiv
report
sentinel
site
assess
frequenc
patient
divers
diseas
diagnost
system
oper
independ
patient
age
although
inher
difficulti
acquir
proper
qualiti
sampl
matrix
infant
eg
sputum
alleg
respiratori
infect
furthermor
test
blood
cultur
polymeras
chain
reaction
pcr
bloodstream
bacteri
infect
diagnost
tool
may
differ
perform
differ
age
group
due
differ
pathogen
load
diagnost
tool
thu
suitabl
case
addit
train
level
user
facil
avail
level
care
target
patient
popul
paramet
develop
novel
diagnost
tool
must
take
consider
extens
debat
regard
whether
diagnost
test
short
timetoresult
applic
laboratori
true
poc
technolog
term
poc
use
test
perform
tree
consid
diagnosi
close
associ
treatment
peripher
level
often
shortag
health
staff
medicin
pointofcar
becom
default
point
proper
care
provid
may
well
clinic
peripher
lab
hospit
depend
wellequip
set
especi
term
human
resourc
divers
avail
diagnost
system
importantli
target
group
local
requir
pose
need
defin
gener
requir
scope
assur
criteria
develop
summar
characterist
ideal
diagnost
test
develop
world
afford
target
group
sensit
specif
userfriendli
limit
train
personnel
rapid
robust
equipmentfre
deliv
need
criteria
initi
develop
sexual
transmit
infect
gener
develop
countriestarget
diagnost
howev
evid
user
requir
call
elabor
finetun
criteria
exampl
equipmentfre
criterion
may
riski
save
test
result
devic
decreas
risk
misinterpret
inexperienc
personnel
therefor
increas
trend
use
mobil
technolog
read
result
provid
later
flow
test
lft
moreov
need
guidanc
select
patient
test
interpret
test
result
clinic
context
triag
patient
refer
admit
due
sever
ill
case
epidem
sever
patient
arriv
simultan
checkpoint
capac
tool
process
sever
sampl
time
advantag
assur
criteria
togeth
addit
specif
requir
summar
target
product
profil
tpp
technolog
develop
meet
develop
stage
exampl
tpp
exist
tuberculosi
ebola
differenti
viral
bacteri
infect
driven
san
msf
foundat
innov
new
diagnost
find
organ
microscopi
screen
malaria
parasit
examin
drop
blood
smear
slide
proper
stain
remain
wide
use
diagnost
tool
giemsastain
thick
thin
blood
film
use
detect
presenc
plasmodium
parasit
quantifi
parasit
densiti
identifi
speci
consid
progress
light
technolog
use
light
emit
diod
led
microscopi
becom
easi
use
howev
still
requir
welltrain
personnel
degre
experi
prepar
sampl
interpret
result
poor
slide
blood
film
prepar
may
lead
artifact
mistaken
parasit
realiti
bacteria
fungi
dirt
cell
debri
consequ
poor
specif
lead
poor
diagnost
qualiti
two
studi
tanzania
shown
low
qualiti
malaria
microscopi
lack
trust
clinician
microscopi
outcom
result
higher
mortal
among
patient
nonmalaria
febril
ill
patient
malaria
addit
major
disadvantag
method
fact
microscopi
identifi
sourc
fever
malaria
except
borreliosi
rel
rare
caus
acut
fever
thu
case
malarianeg
diagnosi
case
coinfect
malaria
viralbacteri
agent
microscopyonli
diagnosi
suffici
clinician
decid
suitabl
treatment
bloodstream
bacteri
infect
includ
typhoid
fever
main
test
use
equip
laboratori
convent
bacteri
cultur
pneumonia
cultur
also
base
respiratori
secret
includ
sputum
imposs
distinguish
chronic
carriag
infect
bronchoalveolar
lavag
pleural
fluid
detect
pneumococc
bacteremia
orient
diagnosi
howev
test
result
low
yield
due
rel
fragil
bacteria
inde
main
gener
drawback
blood
cultur
inabl
except
case
diagnos
local
infect
pneumonia
urinari
tract
infect
typhoid
addit
blood
cultur
stool
cultur
andor
bone
marrow
cultur
use
rare
avail
limit
cultur
take
sever
day
provid
result
collect
high
qualiti
sampl
pediatr
patient
rather
difficult
often
lead
fals
result
adult
sensit
blood
cultur
limit
low
bacteri
load
specif
blood
cultur
also
hamper
contamin
cutan
bacteria
blood
withdraw
sampl
acquisit
two
differ
site
overcom
problem
rather
challeng
practic
especi
children
later
flow
test
consist
plastic
devic
contain
composit
assay
strip
flank
reagentsampl
pad
one
end
absorpt
pad
strip
contain
two
line
stripe
nitrocellulos
membran
one
test
line
consist
diseasespecif
antigen
antibodi
one
line
use
control
thu
antigenor
antibodyspecif
test
perform
reagent
pad
hold
dri
conjug
consist
colloid
goldlabel
antibodi
antigen
specif
test
reaction
perform
ad
sampl
typic
fingerprick
whole
blood
urin
sampl
pad
follow
addit
drop
buffer
sampl
mix
conjug
form
antibodygold
complex
flow
nitrocellulos
membran
specif
antibodiesantigen
present
sampl
bind
respect
conjug
test
zone
indic
posit
result
captur
redcolor
gold
nanoparticl
carri
antibodyantigen
interest
fig
multiplex
possibl
lft
two
way
either
via
multipl
analyt
strip
one
sampl
inlet
via
sever
strip
cassett
mani
inlet
number
strip
former
option
challeng
less
gener
depend
assay
compat
reagent
target
protein
detect
result
read
visual
min
depend
test
valid
test
result
obtain
stain
control
line
observ
equipmentfre
readout
howev
suffici
subject
becom
even
complic
semi
quantit
readout
desir
eg
assess
intens
strip
line
addit
misinterpret
ambigu
test
result
also
risk
data
loss
case
readout
equip
data
storag
transmiss
capac
use
especi
case
multistrip
cassett
use
readout
unit
may
help
diminish
risk
confus
result
differ
line
thu
current
trend
lft
diagnost
toward
autom
readout
dekiread
well
valid
field
malaria
test
sever
technolog
develop
base
colorimetr
eg
colloid
gold
color
latex
fluoresc
detect
commerci
supplier
lft
strip
reader
qiagen
lake
constanc
germani
imag
system
axxin
inc
australia
handheld
imag
captur
lft
reader
detekt
biomed
lcc
usa
reader
lre
medic
germani
handheld
dcn
fluoresc
test
visual
usa
although
system
well
suit
develop
countri
often
afford
lmic
promis
approach
use
smartphon
sever
advantag
system
becom
increasingli
access
africa
ii
use
imag
process
devic
builtin
camera
suitabl
softwar
iii
abl
support
applic
app
process
acquir
data
iv
enabl
global
posit
system
gp
track
patient
epidem
follow
appropri
ethic
rule
relat
permiss
furthermor
data
storag
transmiss
extern
databas
offer
high
ad
valu
lft
camera
also
typic
scan
barcod
lft
cassett
order
identifi
type
test
direct
nonprofit
global
health
organ
global
solut
infecti
diseas
gsid
develop
mobil
tool
read
digit
transmit
poc
diagnost
result
import
infecti
diseas
cooper
univers
washington
seattl
usa
dimagi
boston
usa
gsid
develop
opensourc
softwar
captur
result
mani
differ
poc
test
report
immedi
via
wireless
technolog
proofofconcept
studi
conduct
zimbabw
exampl
approach
mreader
mobil
assay
usa
clearbridg
bioloc
singapor
skansmart
skaneasi
product
skannex
norway
extens
work
field
perform
regard
softwar
develop
exampl
novarum
uk
commcar
mobil
platform
dimagi
usa
due
rel
low
complex
manufactur
lft
manufactur
worldwid
clinic
applic
abl
provid
list
manufactur
averag
price
lft
approxim
us
sever
studi
assess
perform
lft
nonexhaust
list
infect
lft
current
exist
malaria
dengu
typhoid
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
recent
ebola
lassa
howev
averag
qualiti
test
invers
proport
multitud
supplier
often
case
accuraci
inadequ
main
drawback
lft
detect
antibodi
acut
phase
antibodi
often
yet
present
test
lack
sensit
also
dynam
igmigg
complex
hard
interpret
especi
reinfect
possibl
eg
dengu
anoth
problem
antibodi
even
igm
persist
sever
week
acut
infect
decreas
specif
test
eg
chikungunya
reason
standard
oper
procedur
prequalif
publish
regularli
review
recommend
lft
particular
diseas
especi
malaria
hiv
nucleic
acid
amplif
technolog
naat
base
sequencespecif
recognit
amplif
uniqu
target
region
genom
pathogen
detect
thu
naat
highli
specif
sensit
singl
microorgan
detect
compar
microscopi
refer
malaria
diagnosi
naat
much
sensit
contrast
cultur
method
refer
bacteri
diseas
diagnosi
naat
process
time
reduc
day
hour
follow
section
present
frequent
use
naat
polymeras
chain
reaction
pcr
repres
commonli
use
naatbas
diagnost
technolog
reaction
thermost
polymeras
taq
thermu
aquaticu
employ
two
primer
use
flank
target
region
templat
dna
amplifi
threestep
process
time
denatur
step
doublestrand
dna
dsdna
templat
denatur
result
two
singlestrand
dna
ssdna
molecul
ii
primer
anneal
step
primer
hybrid
ssdna
target
region
amplifi
iii
elong
step
polymeras
gener
copi
amplicon
target
region
start
primer
direct
ideal
reaction
target
region
templat
dna
doubl
cycl
endpoint
amplicon
detect
via
gelelectrophoresi
nonspecif
method
use
differ
kind
specif
molecular
probe
gener
ampliconspecif
signal
signal
also
depend
templat
concentr
need
cyclic
heat
cool
perform
previous
describ
step
pcr
render
method
rel
timeconsum
sever
hour
depend
configur
thermocycl
energyconsum
power
suppli
requir
recent
advanc
method
dna
amplif
use
isotherm
naat
inaat
overcom
need
thermal
cycl
method
less
energi
consum
pcr
potenti
execut
batteri
solar
panel
oper
devic
import
advantag
applic
point
care
furthermor
consequ
continu
amplif
rather
cycl
reaction
often
gener
detect
product
faster
pcr
disadvantag
inaat
gener
refer
specif
method
quantit
difficult
follow
strictli
control
reaction
scheme
method
mention
next
section
rna
also
amplifi
addit
revers
transcriptas
rt
transcrib
rna
complementari
dna
cdna
amplif
follow
section
main
isotherm
amplif
technolog
briefli
describ
nucleic
acid
sequenc
base
amplif
nasba
use
detect
rna
perform
due
fact
target
rna
nasba
first
use
rapid
diagnosi
quantif
nasba
reaction
facilit
three
enzym
avian
myeloblastosi
viru
revers
transcriptas
rnase
h
rna
polymeras
lead
amplif
product
brief
amplif
process
cdna
initi
produc
rna
templat
primer
primer
anneal
templat
rna
revers
transcript
form
cdna
latter
cdna
product
rnase
h
hydrolyz
rna
templat
result
cdna
promot
sequenc
anneal
second
primer
primer
doublestrand
dna
dsdna
produc
revers
transcript
follow
step
rna
polymeras
transcrib
rna
molecul
previous
gener
dsdna
procedur
cyclic
round
number
produc
rna
increas
uniqu
advantag
method
select
amplifi
rna
presenc
high
dna
background
process
also
start
dna
templat
case
rnase
h
step
noncycl
phase
necessari
nasba
amplif
nucleic
acid
sequenc
copi
accomplish
min
loopmedi
isotherm
amplif
lamp
develop
eiken
chemic
base
bst
polymeras
strand
displac
activ
thermal
denatur
dsdna
requir
polymeras
denatur
dsdna
prior
elong
due
reaction
temperatur
employ
dsdna
metast
condit
structur
may
hybridizedehybrid
spontan
enabl
primer
bind
templat
dna
melt
region
six
primer
use
result
high
specif
forward
backward
primer
togeth
forward
inner
primer
fip
backward
inner
primer
bip
gener
artifici
start
structur
singlestrand
loop
region
end
base
dumbbel
structur
cauliflowerlik
structur
gener
fip
bip
primer
bind
loop
region
loop
primer
lf
lb
may
help
decreas
reaction
time
process
result
fast
gener
dsdna
product
detect
either
intercal
dye
specif
probe
potenti
min
short
lamp
advantag
due
high
specif
use
minimum
four
primer
defin
six
bind
site
target
ii
sensit
equal
higher
pcr
iii
robust
inhibit
compound
recombinas
polymeras
amplif
rpa
typic
perform
recombinaseprim
filament
scan
templat
dna
homolog
sequenc
match
found
recombinas
mediat
hybrid
primer
complementari
sequenc
denatur
part
templat
dna
stabil
singlestrand
bind
ssb
protein
polymeras
extend
primer
complementari
templat
sequenc
due
low
reaction
temperatur
reaction
may
start
addit
mg
may
necessari
especi
applic
ambient
temperatur
reaction
temperatur
recent
intern
qualiti
assess
molecular
detect
rift
valley
fever
viru
via
rpa
perform
equal
well
best
rtpcr
test
helicasedepend
amplif
hda
typic
perform
two
primer
use
initi
dna
replic
polymeras
first
step
dsdna
unwind
activ
helicas
exploit
achiev
denatur
subsequ
primer
anneal
singlestrand
dna
extend
dna
polymeras
dna
duplex
doubl
one
cycl
produc
dsdna
molecul
separ
helicas
chain
reaction
repeat
similar
rpa
singlestrand
bind
protein
use
stabil
denatur
ssdna
templat
simplic
method
uncompl
cycl
reaction
high
speed
especi
circular
hda
chda
speed
reach
bp
major
advantag
hda
hda
demonstr
effici
sever
differ
type
sampl
matric
includ
urin
stool
blood
plasma
promis
dna
isotherm
amplif
techniqu
strand
displac
amplif
sda
nick
enzym
amplif
reaction
near
strand
invas
base
amplif
siba
roll
circl
amplif
rca
avail
advantag
variou
applic
despit
advantag
naat
regard
sensit
drawback
rel
high
cost
reagent
compar
cost
lft
main
cost
driver
naat
typic
amplif
enzym
polymeras
cost
increas
viral
rna
amplifi
revers
transcriptas
incorpor
reaction
mix
case
inaat
assay
design
complic
exampl
primer
design
lamp
simultan
use
three
enzym
requir
nasba
cost
increas
enzym
prestor
liquid
dri
format
eg
lyophil
approach
may
requir
help
enzym
stabil
challeng
environment
condit
tropic
region
howev
enzym
activ
loss
may
observ
lyophil
compar
liquid
reagent
problem
may
aris
naat
inher
measur
live
dead
pathogen
provid
templat
dna
may
lead
fals
posit
diagnosi
exampl
monitor
progress
patient
treatment
period
infrastructur
point
view
special
laboratori
facil
need
case
welltrain
personnel
must
also
employ
achiev
proper
assay
setup
case
multiplex
assay
risk
human
error
eg
pipet
error
increas
even
experienc
personnel
reach
satisfi
sensit
gener
still
necessari
purifi
nucleic
acid
raw
sampl
materi
blood
sputum
urin
purif
process
may
repres
manual
workload
labor
cost
manual
workflow
add
substanti
overal
cost
section
summar
poc
nearpati
platform
nucleic
acid
extract
amplif
repres
big
categori
emerg
promis
technolog
address
endus
need
express
section
overcom
challeng
outlin
section
relat
lack
autom
context
naat
mention
section
integr
autom
system
order
overcom
need
special
personnel
well
laboratori
infrastructur
includ
reagent
prestorag
system
full
handsoff
oper
autom
platform
must
withstand
challeng
environment
condit
temperatur
humid
tropic
region
dozen
technolog
diagnost
variou
stage
develop
use
variou
set
detect
variou
target
list
long
would
imposs
includ
present
review
aim
provid
list
exist
technolog
present
appli
context
defin
previou
section
within
framework
appli
specif
methodolog
follow
certain
inclusionexclus
criteria
select
technolog
present
particular
includ
focu
febril
ill
syndrom
infecti
diseas
potenti
expand
febril
ill
thu
exclud
technolog
blood
chemistryclin
chemistri
analyz
ii
includ
least
nucleic
acid
amplif
test
also
combin
immunoassay
thu
exclud
technolog
cell
count
iii
least
late
stage
develop
precommerci
commerci
stage
thu
exclud
academ
research
laboratorylevel
solut
descript
platform
divid
two
section
perform
well
technolog
oper
principl
behind
platform
former
refer
issu
portabl
modular
timetoresult
etc
latter
describ
core
technic
compon
main
innov
featur
eg
detect
technolog
fluidic
handl
manufactur
technolog
short
term
detect
technolog
platform
use
optic
method
fluoresc
realtim
signal
monitor
imag
mode
light
scatter
thu
appear
progress
labelfre
technolog
still
requir
reach
commerci
level
except
use
silicon
nanowir
detect
use
integr
lft
ii
regard
fluidic
noteworthi
describ
technolog
implement
microfluid
also
macro
fluidic
particular
ml
liat
use
cartridg
incorpor
macrofluid
handl
eg
syring
plung
fluid
handl
mostli
pressuredriven
although
centrifug
microfluid
increasingli
use
eg
labdisk
mdx
iii
manufacturingwis
major
cartridg
plastic
dispos
except
base
cmo
complementari
metaloxidesemiconductor
technolog
chip
silicon
nanowir
array
iv
term
amplif
platform
allow
dna
rna
analysi
use
rtpcr
although
isotherm
amplif
also
increasingli
use
eg
labdisk
notabl
assembl
assaycartridgeinstru
common
case
constitut
platformbas
approach
regard
perform
platform
aim
singl
pathogen
eg
liat
mdx
other
follow
syndrom
approach
offer
panel
sever
pathogen
simultan
test
eg
biosystem
labdisk
furthermor
import
emphas
mani
technolog
sampletoansw
time
h
except
liat
cost
rang
ten
us
cartridg
sever
thousand
us
instrument
therefor
naat
seem
outcompet
lft
howev
ad
valu
multiplex
naat
platform
offer
comparison
lft
taken
account
moreov
cost
consid
broad
perspect
take
account
hidden
materi
labor
cost
compar
standard
care
comprehens
overview
technolog
technic
featur
shown
tabl
perform
featur
eg
timetoresult
portabl
mention
platform
descript
tabl
latter
intend
focu
mostli
technic
aspect
furthermor
inform
provid
regard
perform
characterist
base
uptod
search
publicli
avail
resourc
author
exclud
possibl
data
may
updat
futur
developersmanufactur
progress
platform
manufactur
termin
delay
developmentmanufacturingmarket
entri
due
corpor
financi
reason
furthermor
tabl
summar
custom
relat
inform
price
instrument
test
pathogenssyndrom
detect
regulatori
statu
inform
provid
platform
public
inform
avail
may
vari
european
us
market
system
fig
cepheid
wide
use
system
develop
countri
implement
molecular
diagnost
identifi
tuberculosi
tb
despit
complex
cartridg
assembl
five
part
system
adopt
resourcelimit
countri
due
endors
mtbrif
test
tb
financi
support
global
fund
aid
malaria
tuberculosi
system
contain
sever
addit
version
detect
drugresist
tb
hiv
mrsa
chlamydia
trachomati
neisseria
gonorrhea
includ
ebola
test
outbreak
timetoresult
estim
min
system
seri
develop
singlecartridg
multicartridg
configur
endus
decid
option
suitabl
need
lowmedium
throughput
system
pointofcar
high
throughput
station
central
laboratori
portabl
system
seri
aim
truli
decentr
tb
diagnosi
omni
fig
b
singlecartridg
version
batteri
oper
wirelessli
connect
cloud
oper
also
via
smartphon
allow
highli
decentr
util
realtim
data
transmiss
price
test
us
us
market
howev
special
arrang
ngo
subsid
test
tb
develop
countri
thu
eventu
cost
slightli
us
exclud
ship
distribut
sale
price
ex
work
iv
devic
cost
approxim
us
omni
cost
less
us
sampletoansw
system
sampl
prepar
extract
nucleic
acid
take
place
cartridg
autom
way
necessari
reagent
prestor
minut
handson
step
requir
liquefact
crude
sampl
sputum
regard
fluidic
cartridg
contain
total
chamber
reservoir
fig
core
cylindr
rotari
valv
handl
plunger
rod
move
vertic
soon
cartridg
insert
process
devic
interfac
valv
plunger
activ
liquid
sampl
prestor
liquid
reagent
movement
chamber
posit
neg
pressur
small
open
base
reservoir
import
compon
cartridg
integr
filter
locat
base
valv
bodi
captur
microorgan
subsequ
sonic
horn
approach
filter
area
mediat
mechan
lysi
microorgan
releas
nucleic
acid
latter
pump
chamber
bead
freezedri
amplif
reagent
store
rehydr
upon
suffici
fill
correspond
chamber
fill
level
act
also
intern
fluidic
qualiti
control
entir
mixtur
direct
pcr
reaction
tube
locat
back
cartridg
regard
detect
pcr
tube
surround
heatingcool
plate
enabl
fast
thermal
respons
optic
block
enabl
amplif
realtim
fluorescencebas
pcr
product
detect
contrast
tradit
thermal
cycl
system
sampl
subject
timetemperatureopt
protocol
sampl
system
subject
differ
protocol
one
innov
featur
process
modul
intellig
coolingh
optic
reaction
icor
modul
sophist
solidst
miniatur
microelectron
microopt
system
capabl
perform
pcr
reaction
multichannel
fluoresc
detect
min
icor
includ
fourchannel
optic
system
capabl
excit
detect
multipl
fluoresc
dye
reaction
tube
therebi
abl
accur
measur
four
dna
target
simultan
fig
benchtop
diagnost
instrument
three
fdaclear
panel
respiratori
panel
blood
cultur
identif
panel
gastrointestin
panel
respond
ebola
outbreak
receiv
emerg
use
author
eua
us
fda
base
biothreat
panel
specif
detect
ebola
zair
field
studi
conduct
sierra
leon
patient
healthcar
worker
minut
handson
prepar
time
requir
cartridg
insert
process
devic
includ
load
pouch
load
block
insert
hydrat
solut
pouch
load
sampl
simplic
use
lack
refriger
storag
requir
multiplex
capac
posit
featur
use
limit
train
personnel
differ
target
analyz
per
test
yet
throughput
still
low
one
patient
screen
per
test
run
addit
manufactur
list
price
reader
us
reagent
us
may
afford
resourcelimit
set
sampletoansw
system
whose
core
technolog
base
freezedri
vacuum
reagent
pouch
nest
multiplex
pcr
allow
detect
multipl
organ
microfluid
pouch
fig
b
consist
two
area
name
fitment
reagent
preload
freezedri
main
bodi
two
bond
via
heat
weld
fitment
fabric
inject
mold
polypropylen
main
bodi
fabric
two
sheet
polyesterpolypropylen
film
contain
copolym
adhes
layer
layer
weld
togeth
use
heat
plate
fitment
contain
reservoir
fig
b
contain
biochem
reagent
entir
manufactur
process
vacuum
maintain
well
set
plung
b
import
maintain
vacuum
fitment
blister
help
maintain
freezedri
natur
compon
thu
longterm
storag
ii
allow
inject
sampl
hydrat
solut
pouch
correct
volum
iii
minim
format
bubbl
microfluid
system
sampl
matrix
nasopharyng
swab
respiratori
panel
differ
matric
use
panel
total
liquefi
sampl
sampl
lysi
buffer
use
test
user
inject
hydrat
buffer
use
rehydr
freezedri
prestor
reagent
sampl
two
differ
design
inlet
vacuum
pouch
automat
draw
correct
volum
thu
elimin
need
precis
measur
pipet
user
liquid
handl
appli
pneumat
pressur
bladder
assembl
contain
bladder
plate
sever
inflat
bladder
locat
correspond
one
chamber
pouch
assembl
subject
differ
ga
pressur
bladder
extern
contact
pouch
chamber
chang
volum
bladder
caus
liquid
move
chamber
pouch
bladder
press
pneumaticallydriven
piston
fig
sampl
move
lysi
chamber
perform
mechan
lysi
bead
beat
use
ceram
zirconium
silic
bead
procedur
follow
boom
chemistri
releas
nucleic
acid
bound
silicaco
magnet
bead
transport
lysi
chamber
purif
chamber
use
magnet
integr
devic
chamber
remain
cellular
viral
debri
remov
wash
elut
step
releas
nucleic
acid
magnet
bead
stage
pcr
follow
cycl
includ
revers
transcript
step
convert
rna
cdna
dozen
primer
pair
target
molecul
mix
multiplex
pcr
dilut
step
follow
addit
mixtur
fresh
mastermix
contain
intercal
fluoresc
dna
dye
subsequ
mixtur
aliquot
highdens
array
microfluid
well
stage
nest
pcr
take
place
pcr
use
elimin
limit
associ
singlestep
multiplex
pcr
end
stage
pcr
temperatur
slowli
increas
fluoresc
well
measur
creat
melt
curv
shape
posit
use
differenti
amplif
product
differ
melt
temperatur
two
stage
pcr
instrument
two
peltier
element
blue
led
use
illumin
array
stage
pcr
fluoresc
emit
dye
imag
ccd
camera
aler
inc
market
molecular
diagnost
pointofcar
system
fig
detect
influenza
b
human
respiratori
syncyti
viru
rsv
well
group
streptococcu
cliawaiv
differ
cartridg
viru
bacterium
detect
recent
studi
shown
system
exhibit
least
equal
superior
sensit
convent
rapid
test
rapid
isotherm
amplif
technolog
implement
near
enabl
sampletoansw
analysi
within
min
instrument
portabl
standalon
need
laptop
userfriendli
interfac
data
storag
capac
interfac
abil
test
price
approxim
us
devic
cost
approxim
us
sampl
matrix
nasopharyng
swab
elut
transport
medium
analysi
procedur
sampl
answer
prestor
reagent
singl
use
dispos
test
cartridg
consist
three
part
fig
test
base
insert
first
avail
devic
slot
test
base
two
reaction
tube
contain
lyophil
pellet
pair
templat
similar
primer
specif
amplif
target
nucleic
acid
fluorescentlylabel
molecular
beacon
design
specif
identifi
amplifi
target
sampl
receiv
insert
second
avail
devic
slot
cartridg
contain
elut
buffer
elut
pathogen
swab
stir
swab
cartridg
transfer
cartridg
press
sampl
receiv
collect
necessari
amount
materi
transfer
lock
test
base
order
initi
amplif
amplifi
product
detect
via
dualchannel
fluoresc
deriv
fluoresc
probe
indepth
technic
design
inform
regard
cartridg
publicli
avail
detail
system
anoth
system
manufactur
q
detect
fig
fulli
autom
platform
detect
within
min
base
realtim
pcr
multiplex
capabl
suitabl
pointofcar
use
due
portabl
natur
batteri
oper
laptop
requir
easi
use
touch
screen
cartridg
store
room
temperatur
without
need
cold
chain
q
platform
launch
multipl
develop
countri
initi
qualit
hiv
allow
fingerprick
detect
hiv
viru
whole
blood
collect
directli
cartridg
suffici
insert
instrument
autom
process
extract
amplif
detect
technolog
oper
principl
q
q
detect
sampletoansw
system
lysi
base
chaotrop
salt
act
upon
sampl
releas
nucleic
acid
biotinyl
oligonucleotid
specif
genom
hybrid
postlysi
releas
viral
rna
subsequ
bound
streptavidinsepharos
particl
wash
revers
transcript
pcr
follow
detect
pcr
product
core
technolog
innov
system
base
competit
report
monitor
amplif
cma
technolog
util
array
immobil
oligonucleotid
probe
complementari
fluoresc
label
report
oligonucleotid
solut
report
compet
amplicon
hybrid
surfac
probe
begin
amplicon
label
report
hybrid
surfaceprob
thu
initi
signal
high
pcr
reaction
progress
label
report
prefer
bind
amplicon
therefor
less
report
bound
microarray
consequ
progress
pcr
monitor
via
decreas
fluoresc
microarray
spot
plateau
amplif
reaction
reach
fluoresc
imag
follow
progress
reaction
one
imag
collect
anneal
cycl
regard
fluidic
fig
b
sampl
insert
capillari
posit
inlet
special
design
receiv
fingerheel
prick
control
window
help
user
assess
fill
level
cap
ensur
hermet
seal
minim
risk
sampl
spill
aerosol
exit
cartridg
therebi
avoid
contamin
risk
dri
reagent
prestor
intern
compart
along
buffer
reservoir
fluidic
network
valv
cartridg
regul
liquidair
movement
septum
prick
needl
connect
pneumat
modul
cartridg
use
appli
air
pressur
move
liquid
differ
compart
compart
reaction
chamber
pcr
take
place
microarray
locat
ml
fig
pointofcar
platform
commerci
diagnost
sinc
process
sell
intellectu
properti
underli
pointofcar
molecular
diagnost
platform
nevertheless
platform
describ
one
repres
one
although
main
applic
system
respiratori
tract
infect
function
perform
characterist
would
enabl
potenti
use
febril
ill
diagnosi
indic
pipelin
infecti
diseas
includ
influenza
b
well
rsv
ml
requir
laptop
due
intern
control
userfriendli
touch
screen
instrument
avail
modular
configur
ie
singlemodul
sixmodul
option
one
six
cartridg
respect
modul
oper
independ
via
central
control
therefor
differ
assay
requir
differ
protocol
differ
specimen
perform
time
overal
analysi
time
modul
min
analyt
diagnost
verif
process
fluabrsv
assay
ml
led
subsequ
ce
mark
complet
juli
guy
st
thoma
nh
foundat
trust
london
uk
molecular
analysi
base
realtim
pcr
requir
reagent
prestor
cartridg
allow
fulli
autom
analysi
short
handson
time
min
need
cold
chain
reagent
store
ambient
temperatur
biochem
analysi
initi
combin
thermal
chemic
lysi
releas
nucleic
acid
captur
magnet
bead
magnet
bead
robot
transfer
situ
two
wash
buffer
purif
remov
inhibitori
agent
last
step
amplif
elut
nucleic
acid
bead
follow
mix
amplif
reagent
freezedri
test
contain
bacteriophag
intern
process
control
cartridg
consist
three
main
block
fig
sampl
inlet
block
swab
introduc
collect
tube
clamp
onto
cartridg
ii
block
prestor
liquid
reagent
indic
yellow
fig
iii
block
specif
tool
movabl
compon
pipettor
magnet
wand
foil
cutter
core
cartridg
oper
base
robot
actuat
fluid
vessel
order
facilit
biochem
reaction
handl
bead
etc
particular
robot
arm
pick
movabl
item
insert
correspond
liquid
tube
highli
innov
featur
system
pcr
reaction
vessel
consist
electr
conduct
polym
ecp
act
resist
heat
element
time
arrang
way
electr
conduct
profil
differ
differ
area
vessel
along
axi
therebi
control
thermal
gradient
necessari
thermocycl
differ
electr
conduct
profil
regul
manufactur
vessel
vari
radial
thick
key
paramet
thu
vari
unevenli
resist
profil
vessel
consist
combin
highli
conduct
materi
aluminum
ecp
two
separ
insul
layer
aforement
induc
temperatur
gradient
also
assist
convectionbas
liquid
mix
reaction
vessel
ecp
fabric
technolog
typic
inject
mold
detect
achiev
via
hybrid
probe
fluoresc
reson
energi
transfer
fret
take
advantag
effect
ml
system
use
two
probe
hybrid
amplifi
dnarna
product
act
energi
donor
acceptor
amplif
occur
two
probe
hybrid
locat
close
proxim
thu
energi
donor
induc
excit
sourc
transfer
acceptor
turn
emit
energi
fluoresc
latter
monitor
real
time
amplif
process
amount
acceptor
fluoresc
proport
amount
gener
pcr
product
roch
diagnost
offer
liat
labinatub
system
compact
solut
pointofcar
molecular
diagnost
fig
system
current
use
detect
influenza
b
rsv
viral
rna
nasopharyng
swab
specimen
patient
sign
symptom
respiratori
infect
conjunct
clinic
epidemiolog
risk
factor
ii
streptococcu
pyogen
group
streptococcu
strep
throat
swab
specimen
patient
sign
symptom
pharyng
howev
multiplex
system
aforement
infect
detect
differ
cartridg
instrument
compact
standalon
laptopfre
small
footprint
oper
way
minim
possibl
interfer
contamin
user
minimum
train
need
system
provid
result
fast
min
cost
devic
cartridg
approxim
respect
although
system
yet
use
febril
ill
diagnosi
develop
countri
perform
featur
make
good
candid
technolog
oper
principl
liat
sampletoansw
platform
thank
full
integr
necessari
reagent
cartridg
situ
sampl
prepar
start
mix
sampl
chaotrop
agent
induc
pathogen
lysi
follow
bindwashelut
protocol
boomchemistri
involv
bind
nucleic
acid
silicashel
magnet
bead
subsequ
wash
final
elut
step
nucleic
acid
readi
realtim
pcr
intern
control
core
technolog
system
cartridg
consist
rigid
frame
transpar
flexibl
tubul
latter
consist
sever
pouch
segment
separ
via
breakabl
seal
flexibl
enough
compress
system
use
peristalt
fluidic
actuat
liquid
handl
cartridg
load
analyz
contain
clamp
plung
actuat
control
select
releas
reagent
tube
segment
lead
mix
propuls
liquid
precis
appli
pressur
pouch
pressur
need
compress
tubul
unload
pouch
approxim
atm
analyz
also
provid
control
reaction
condit
differ
temperatur
altern
movement
reaction
mix
two
differ
temperatur
zone
rapid
pcr
fig
outcom
reaction
appear
realtim
fluoresc
signal
detect
sixchannel
photomet
modul
analyz
fabric
perspect
tubul
base
polyolefin
fabric
via
inject
mold
blow
mold
order
serv
specif
process
need
tubul
surfaceprocess
via
plasma
treatment
introduct
addit
wall
materi
multilay
inner
layer
biocompat
outer
resist
ga
permeabl
flexibl
tubul
support
rigid
frame
made
polypropylen
lower
melt
temperatur
tubul
ensur
uniform
melt
seal
accord
relev
patent
although
patent
ensur
exact
method
use
final
product
seal
compon
achiev
via
weld
flexibl
tubul
outer
frame
use
thermal
andor
ultrason
sourc
altern
approach
seal
two
compon
hotmelt
adhes
joint
ethylen
vinyl
acet
uv
cure
epoxi
dimens
frame
surround
tubul
cartridg
mm
height
mm
width
agenc
scienc
technolog
research
star
singapor
stmicroelectron
itali
veredu
laboratori
singapor
partner
develop
labonachip
diagnosi
infecti
diseas
fig
system
alreadi
market
use
brazilian
author
tool
choic
world
cup
number
applicationspecif
cartridg
develop
respiratori
infect
tuberculosi
biothreat
agent
anthrax
small
pox
plagu
tularemia
multipl
avian
pathogen
middl
east
respiratori
syndrom
coronaviru
partnership
announc
launch
multipl
tropic
diseas
provid
necessari
multiplex
febril
ill
diagnosi
requir
cost
per
test
approxim
us
sampl
prepar
perform
ex
situ
either
via
spin
column
autom
extract
kit
overal
timetoresult
includ
extract
amplif
optic
readout
add
approxim
h
assay
chip
multi
drug
resist
tuberculosi
clinic
valid
core
system
base
labonachip
cartridg
incheck
platform
fig
size
standard
microscop
slide
contain
silicon
chip
cover
glass
coverslip
bond
plastic
support
onchip
print
circuit
board
pcb
provid
necessari
electr
contact
interfac
process
instrument
eg
temperatur
control
silicon
chip
distinct
process
area
fig
sampl
inlet
microfluid
port
buri
microchannel
facilit
easi
chip
fill
fluid
displac
ii
pcr
area
mm
contain
four
pcr
chamber
liquid
volum
capac
four
pair
independ
control
aluminum
resistor
use
heat
silicon
substrat
fluidic
reactor
thu
provid
thermocycl
environ
temperatur
regul
temperatur
control
system
tc
chip
process
devic
iii
outlet
hole
provid
microfluid
contact
iv
postpcr
hybrid
detect
area
consist
mm
microarray
spot
oligonucleotid
probe
spot
use
piezoarray
system
fabric
perform
semiconductorbas
mem
process
technolog
name
simich
wafer
diamet
allow
fabric
micromechan
sensor
microfluid
compon
detail
process
step
avail
fig
show
key
microfabr
compon
chip
crosssect
view
entir
labonachip
devic
postfabr
process
includ
surfac
chemic
treatment
order
immobil
dna
probe
microarray
area
achiev
biocompat
pcr
area
dna
amplif
postamplif
detect
perform
separ
dedic
instrument
fluoresc
microarray
detect
chiphybrid
amplif
product
use
imag
acquisit
camera
quantumdx
ukbas
nanomedtech
compani
develop
commerci
afford
handheld
sampletoresult
diagnost
dna
sequenc
technolog
use
nanowir
biosensor
innov
microfluid
technolog
collabor
institut
microelectron
ime
agenc
scienc
technolog
research
star
singapor
strateg
fabric
key
microelectron
compon
platform
fig
quantumdx
handheld
batterypow
molecular
diagnost
devic
promis
sampletoansw
dnabas
result
min
contain
integr
reagent
current
stabil
target
month
system
test
one
patient
per
run
pioneer
approach
handheld
sequenc
market
quantumdx
partner
find
order
develop
solut
combin
detect
tb
drug
suscept
determin
caus
agent
tb
system
seem
especi
promis
antimicrobi
resist
profil
given
mani
differ
gene
screen
nanowir
array
sever
assay
pipelin
diagnosi
eg
hiv
sexual
transmit
infect
neglect
diseas
well
tumor
profil
core
lie
biosensor
chip
equip
silicon
nanowir
sinw
array
base
fieldeffect
biosensor
sinw
larg
surfacetovolum
ratio
tunabl
electr
properti
exhibit
high
potenti
biosensor
thu
enabl
nextgener
pointofcar
diagnost
bind
event
detect
labelfre
way
chang
nanowir
resist
effect
convert
genet
code
binari
code
provid
output
digit
format
particular
upon
hybrid
target
dna
sinw
charg
densiti
subsequ
electr
field
chang
reflect
chang
resist
nanowir
produc
biosens
signal
fig
neg
charg
present
hybrid
higher
resist
ntype
sinw
sensor
principl
shown
zhang
et
al
vari
hybrid
site
thu
vari
distanc
charg
layer
keep
total
number
charg
unchang
function
sinw
perform
peptid
nucleic
acid
pna
instead
dna
oligonucleotid
neutral
natur
pna
minim
format
dens
charg
layer
near
nanowir
surfac
subsequ
minim
signal
nois
ratio
ntype
sinw
featur
typic
dimens
w
h
l
nm
nm
fabric
use
standard
cmoscompat
topdown
approach
oxid
polysilicon
beam
pattern
use
convent
photolithographi
ptype
test
wafer
detail
avail
gao
et
al
method
compat
massmanufactur
reproduc
conveni
allow
scale
sens
area
multiplex
requir
applic
capac
nanowir
silicon
biosensor
chip
multiplex
potenti
becom
huge
sampletoansw
oper
achiev
hous
biosensor
chip
microfluid
cartridg
fig
ustar
biotechnolog
hangzhou
ltd
commerci
proprietari
isotherm
amplif
technolog
equipmentfre
diagnost
system
fig
therefor
system
especi
attract
resourcelimit
set
intend
batch
test
microscopi
center
howev
system
lack
multiplex
targetcartridg
requir
handson
extract
step
centrifug
vortex
syring
extract
perform
ex
situ
use
equipmentfre
extract
kit
boil
lysi
syring
use
extract
elut
dna
use
appropri
buffer
initi
test
kit
perform
clinic
studi
tanzania
china
tuberculosi
manufactur
note
reagent
requir
refriger
storag
system
base
isotherm
amplif
method
call
cross
prime
amplif
cpa
use
multipl
crosslink
primer
amplifi
dna
rna
constant
temperatur
reprint
permiss
copyright
american
chemic
societi
due
isotherm
natur
amplif
requir
complex
temperatur
control
system
water
bath
heat
block
use
order
maintain
constant
temperatur
incub
cpa
assay
follow
min
amplif
step
reaction
tube
transfer
cartridg
later
flow
immunochromatograph
strip
provid
visual
readout
min
patent
crosscontaminationproof
xcp
nucleic
acid
detect
devic
fig
offer
advantag
minim
risk
amplicon
crosscontamin
maintain
close
reaction
tube
amplif
thu
avoid
releas
amplicon
aerosol
ii
use
enclos
unit
amplicon
tube
insert
reaction
tube
iii
place
amplicon
tube
addit
enclos
unit
detect
devic
run
buffer
reaction
tube
insert
amplicon
cartridg
amplicon
cartridg
subsequ
insert
detect
chamber
seal
detect
chamber
close
activ
blade
punctur
simultan
two
tube
run
buffer
drive
amplicon
adjac
later
flow
strip
amplif
result
visual
readabl
fig
c
detect
principl
later
flow
nucleic
acid
test
strip
base
combin
nucleic
acid
hybrid
immunoassay
principl
probe
use
carri
color
particl
hybrid
amplicon
complex
captur
antibodi
nitrocellulos
membran
test
strip
absenc
amplif
product
interactionhybrid
probe
flow
uncaptur
membran
absorb
pad
fig
b
meandershap
microfluid
channel
fill
reagent
releas
area
g
h
particular
reagent
may
includ
variou
nucleotid
mixtur
wash
solut
separ
air
bubbl
order
flow
sequenti
wellcontrol
way
nucleotid
flow
sequenti
nanowireimmobil
singl
strand
oligonucleotid
accord
hybrid
sequenc
local
charg
chang
caus
resist
chang
sinw
imag
sourc
use
luminex
corp
commerci
rp
flex
system
fig
develop
previous
commerci
nanospher
receiv
fda
approv
target
applic
respiratori
tract
infect
system
cover
broad
panel
includ
virus
bacteria
analysi
perform
nasopharyng
swab
also
offer
panel
gastrointestin
also
identifi
eight
gramneg
organ
resist
marker
blood
cultur
fullautom
mode
system
prestor
reagent
requir
minimum
handson
time
min
overal
timetoresult
h
system
benchtop
consist
two
compon
reader
control
processor
sp
perform
autom
test
process
step
modular
system
sinc
one
reader
act
user
interfac
central
control
unit
handl
sever
processor
sp
test
use
four
singleus
consum
extract
tray
tip
holder
assembl
amplif
tray
test
cartridg
load
processor
sp
autom
process
glass
support
test
cartridg
carri
microarray
insert
reader
detect
imag
sourc
use
b
c
reprint
copyright
permiss
elsevi
step
specimen
extract
target
amplif
hybrid
fluidic
handl
perform
via
insystem
servo
actuat
posit
displac
pump
eg
syring
pump
combin
pneumat
valv
comprehens
sequenc
step
provid
one
compani
patent
system
technic
bulletin
sampl
process
extract
amplif
tray
nucleic
acid
transport
test
cartridg
end
procedur
substrat
support
glass
slide
microarray
captur
target
nucleic
acid
must
remov
cartridg
place
reader
readout
take
second
necessari
reagent
contain
cartridg
amplif
technolog
base
multiplex
rtpcr
heat
cool
zone
follow
hybrid
target
specif
captur
oligonucleotid
microarray
format
endpoint
detect
achiev
gold
nanoparticl
aunp
constitut
core
technolog
system
proprietari
nanogrid
technolog
fig
dimens
nm
advantag
aunp
convent
fluorophor
increas
sensit
sever
order
magnitud
eg
light
scatter
one
nanoparticl
equival
light
emit
fluorophor
amplif
complet
workflow
detect
follow
insid
test
cartridg
amplifi
target
hybrid
captur
oligonucleotid
preimmobil
glass
slide
microarray
remov
unbound
dna
hybrid
product
label
aunp
subsequ
intermedi
oligonucleotid
flush
chamber
bind
specif
immobil
complex
leav
polya
tail
stick
avail
subsequ
attach
polytbound
aunp
act
probe
remov
unbound
aunp
captur
aunp
cover
silver
np
analysi
procedur
enhanc
scatter
light
thu
overal
size
np
becom
larger
subsequ
optic
signal
enhanc
illumin
begin
led
max
nm
shine
edg
glass
slide
act
waveguid
led
illumin
evanesc
wave
gener
glass
slide
toward
np
coat
surfac
caus
light
scatter
illumin
ausilvernp
toward
camera
captur
imag
array
multipl
time
variou
exposur
time
notabl
aunpbas
detect
technolog
may
adapt
protein
analysi
well
spanish
molecular
diagnost
compani
statdx
acquir
qiagen
januari
develop
fig
platform
oper
nearpati
test
solut
low
test
volum
platform
cover
midthroughput
requir
compani
announc
earli
approv
ceivd
clearanc
system
respiratori
panel
statdx
expect
full
commerci
launch
quarter
cartridg
prefil
dri
liquid
reagent
shelflif
stabil
month
room
temperatur
cartridg
inocul
either
use
swab
directli
appropri
cartridg
hous
sampl
elut
use
liquid
sampl
volum
ml
autom
cell
lysi
use
releas
nucleic
acid
pathogen
nucleic
acid
purif
follow
use
high
qualiti
extract
column
sampl
subject
rapid
thermocycl
amplif
eight
realtim
pcr
reaction
chamber
sixplex
capabl
allow
simultan
detect
total
target
regard
fluidic
cartridg
includ
transfer
modul
move
later
along
guid
locat
within
cartridg
order
align
variou
fluid
port
control
movement
fluid
cartridg
channel
chamber
fig
show
typic
cartridg
back
side
area
design
number
repres
test
unit
dilutiondos
unit
fluid
guid
unit
variou
chamber
respect
test
unit
shown
detail
fig
b
fluidic
test
arrang
align
graviti
field
order
avoid
format
bubbl
variou
chamber
inlet
port
structur
indic
top
chamber
unvent
act
air
reservoir
air
trap
within
microchannel
avoid
vent
elimin
aerosol
leakag
cartridg
achiev
channel
open
use
fluidic
control
optic
sens
defin
whether
liquid
mix
chamber
includ
larg
crosssect
caus
turbul
liquid
flow
enhanc
mix
passiv
mix
chamber
actual
reaction
chamber
volum
serv
also
detect
chamber
contain
dri
store
reagent
appli
variabl
pressur
inlet
port
liquid
may
push
chamber
rehydr
reagent
pull
back
chamber
order
particip
reaction
structur
indic
fig
b
may
repeat
sever
time
common
inlet
port
differ
store
reagent
order
serv
geometr
multiplex
reaction
concept
centrifug
microfluid
contrast
pressuredriven
microfluid
aforement
platform
use
evolv
matur
power
technolog
autom
diagnost
workflow
field
clinic
chemistri
immunodiagnost
nucleic
acid
analysi
other
microfluid
approach
benefit
particular
straightforward
mechan
liquid
actuat
base
centrifug
forc
result
simpl
rotat
cartridg
defin
spin
frequenc
extern
pressur
sourc
complic
micro
pump
system
requir
reduc
risk
crosscontamin
due
open
cartridg
allow
build
simpl
portabl
process
devic
small
footprint
weight
fact
qualifi
centrifug
microfluid
technolog
autom
diagnost
point
care
main
advantag
centrifug
microfluid
employ
microfluid
modul
unit
oper
one
serv
particular
fluidic
function
liquid
handl
eg
meter
aliquot
valv
switch
pump
mix
assay
integr
reagent
prestorag
suppli
separ
detect
blood
plasma
separ
nucleic
acid
purif
amplif
wash
block
comprehens
overview
unit
oper
process
chain
provid
strohmeier
et
al
combin
unit
oper
process
chain
allow
integr
complex
laboratori
process
one
system
fulli
autom
sampletoansw
analysi
challeng
mainli
field
cartridgeintegr
sampl
prepar
requir
complet
integr
sampletoansw
solut
apart
worldtodisk
interfac
defin
sampl
ad
user
cartridg
prepar
complex
sampl
sputum
classic
specimen
diagnost
eg
detect
tuberculosi
unsolv
issu
yet
sampl
divers
physic
constitut
harsh
chemic
strong
forc
requir
pretreat
challeng
handl
increas
sampl
volum
ml
blood
urin
requir
pathogen
load
low
requir
clinic
sensit
diagnosi
high
maximum
sampl
volum
typic
limit
avail
footprint
disk
consid
eg
nucleic
acid
extract
classic
bindwashelut
chemistri
equal
volum
lysi
bind
buffer
requir
sampl
treatment
henc
pose
challeng
cartridg
integr
reagent
prestorag
research
perspect
increas
applic
diskbas
system
recent
observ
resourcelimit
set
especi
field
immunodiagnost
diskbas
test
detect
fourparamet
liver
assay
panel
defin
liver
function
demonstr
complet
within
min
nwankir
et
al
use
portabl
batteri
power
process
devic
includ
field
test
laboratori
nigeria
furthermor
hosseini
et
al
implement
novel
mix
method
use
microspher
disk
order
detect
dengu
viru
antigen
follow
section
provid
short
overview
centrifug
microfluid
platform
late
develop
market
stage
inclus
criteria
review
technolog
focu
infecti
diseas
least
public
field
one
repres
platform
centrifug
microfluid
late
stage
develop
labdisk
fig
hahnschickard
imtek
univers
freiburg
germani
technolog
appli
varieti
applic
rang
clinic
chemistri
immunoassay
nucleic
acid
analysi
indic
univers
use
latter
field
two
signific
advanc
fulli
autom
sampletoansw
nucleic
acid
extract
amplif
analysi
announc
particularli
neonat
sepsi
detect
warneri
h
influenza
e
coli
agalactia
well
influenza
viru
amplif
base
pcr
timetoresult
h
yet
labdisk
use
integr
rpa
isotherm
amplif
detect
biolog
warfar
pathogen
b
anthraci
f
tularensi
pesti
total
timetoresult
min
addit
process
devic
isotherm
amplif
oper
power
consumpt
w
facilit
applic
remot
environ
potenti
use
batteri
solar
panel
applic
labdisk
point
care
resourcelimit
set
demonstr
detect
yellow
fever
viru
laboratori
field
set
seneg
use
rpa
min
amplif
time
recent
labdisk
develop
detect
malaria
dengu
chikungunya
pneumonia
typhoid
fever
use
lamp
provid
necessari
mean
nucleic
acid
base
multiplex
amplif
timetoresult
min
current
one
disadvantag
labdisk
sever
paramet
analyz
per
disk
one
disk
correspond
one
patient
process
per
test
run
concept
behind
labdisk
translat
laboratori
process
step
microfluid
unit
oper
interfac
toward
fulli
function
sampletoansw
solut
sampl
volum
rang
sub
sever
hundr
one
labdisk
innov
prestorag
liquid
reagent
stickpack
pouch
tightli
seal
buffer
releas
demand
upon
centrifug
manufactur
technolog
microthermoform
polym
foil
technolog
routin
use
macroscal
blister
packag
adapt
microscal
micronanostructur
labdisk
fig
typic
foil
thick
mold
thin
polym
foil
place
mold
heat
temperatur
near
glass
transit
temperatur
polym
foil
condit
favor
air
blown
top
foil
take
shape
mold
main
process
paramet
appli
air
pressur
temperatur
mold
foil
variou
materi
use
prefer
candid
cyclic
olefin
polymercopolym
cop
coc
polycarbon
pc
depend
applic
requir
seal
perform
either
via
pressur
sensit
adhes
foil
contain
nanocapsul
break
releas
adhes
upon
applic
pressur
via
thermal
seal
use
one
foil
materi
eg
coc
coc
elastomer
mold
suitabl
prototyp
fast
iter
requir
howev
elastomer
mold
may
worn
repeat
use
ten
cartridg
thu
larg
manufactur
seri
effici
use
metal
mold
may
challeng
deform
foil
method
coat
metal
use
howev
econom
sustain
durabl
one
metal
mold
suffici
ten
thousand
disk
commerci
point
view
system
fig
genepoc
inc
simpl
integr
portabl
instrument
prevent
earli
detect
infecti
diseas
system
receiv
fda
clearanc
clostridium
difficil
assay
ce
mark
group
b
streptococcu
assay
futur
genepoc
inc
plan
develop
cartridg
detect
respiratori
gastrointestin
neonat
hospitalacquir
infect
well
sexual
transmit
diseas
system
oper
sampletoansw
mode
minimum
handson
step
minut
manufactur
declar
timetoresult
h
importantli
system
oper
standalon
mode
without
need
laptop
replac
touch
screen
instead
univers
sampletocartridg
interfac
accept
liquefi
matrix
allow
compat
sever
type
swab
urin
etc
cartridg
consist
three
piec
plastic
wedgeshap
form
unlik
entir
disk
allow
devic
process
eight
cartridg
simultan
thu
offer
increas
throughput
often
necessari
case
extrem
poc
test
dispos
compos
three
distinct
oper
sector
worldtochip
interfac
clinic
sampl
condit
sampl
buffer
insert
dispos
transfer
pipett
develop
mention
use
blood
feasibl
yet
would
requir
offchip
microbi
preconcentr
subsequ
inlet
chamber
seal
lid
prevent
aerosol
leakag
seri
siphon
passiv
valv
prime
liquid
next
chamber
ii
univers
sampl
prepar
start
pathogen
mechan
lysi
metal
disk
magnet
actuat
chamber
glass
bead
present
lead
effici
lysi
releas
nucleic
acid
lysat
centrifug
driven
dilut
chamber
pcr
inhibitor
inactiv
heat
proper
ionic
condit
adjust
extract
materi
order
optim
subsequ
amplif
iii
amplif
detect
sector
assayspecif
area
cartridg
rtpcr
perform
reagent
drystor
sector
three
chamber
avail
amplif
thermocycl
achiev
via
air
heat
overal
process
chamber
devic
includ
four
nonoverlap
excit
emiss
wavelength
fluoresc
detect
chemic
dye
therefor
target
chamber
detect
simultan
rotat
detail
regard
cartridg
materi
fabric
method
avail
manufactur
mdx
fig
formerli
cycler
integr
assay
centrifugalbas
autom
platform
commerci
diasorin
inc
formerli
focu
diagnost
current
own
part
diasorin
group
system
acquir
fdaceivd
approv
target
applic
current
aim
respiratori
tract
infect
influenza
b
well
rsv
virus
hsv
group
streptococcu
c
difficil
system
classifi
benchtop
oper
via
laptop
cost
per
cartridg
approxim
instrument
cost
approxim
devic
compat
two
type
disk
target
differ
type
endus
specif
made
polypropylen
nucleic
acid
compat
adhes
direct
amplif
disk
eight
individu
slotscartridg
connect
one
disk
one
use
simultan
sampl
volum
mix
buffer
sampletoansw
time
min
base
highspe
thermocycl
rapid
rtpcr
use
high
heatingcool
rate
respect
sampl
requir
preprocess
dnarna
extract
direct
amplif
applic
ii
univers
disk
singleus
cartridg
abl
perform
multipl
assay
per
disk
reaction
volum
devic
four
excit
emiss
wavelength
optic
multiplex
addit
geometr
multichamb
multiplex
univers
disk
use
extract
perform
ex
situ
eluat
insert
disk
rather
differ
approach
typic
benchtopbas
fullyautom
system
suggest
diagnosticsinasuitcas
dia
initi
develop
emerg
avian
influenza
viru
contrast
aforement
system
core
micro
fluidic
cartridg
handl
fulli
autom
way
dia
system
proclaim
miniatur
fullyintegr
compon
requir
handson
step
yet
smartli
includ
necessari
biochem
compon
extract
amplif
reagent
tool
glove
pipett
tube
track
pipett
box
wast
contain
equip
tube
scanner
vortex
microcentrifug
even
mask
case
highli
infecti
diseaseepidem
within
suitcas
complet
onsit
analysi
entir
portabl
lab
function
solar
panel
power
pack
fig
workflow
includ
typic
sampl
prepar
start
lysi
pathogen
extract
nucleic
acid
bind
magnet
bead
two
wash
step
elut
process
requir
min
subsequ
amplif
step
conduct
via
rtrpa
timetoposit
min
total
nine
pipet
step
requir
reduc
replac
liquid
compon
lyophil
reagent
ebola
outbreak
system
appli
field
trial
guinea
collabor
institut
pasteur
dakar
public
health
institut
guinea
univers
stirl
robert
koch
institut
twistdx
ltd
innov
approach
tackl
sever
problem
includ
lack
constant
electr
lack
cold
chain
materi
storag
risk
time
loss
transfer
infecti
materi
field
central
laboratori
analysi
need
fast
timetoresult
healthcar
provid
screen
patient
ebola
viru
natur
drawback
dia
system
lack
connect
accompani
consequ
manual
registr
data
risk
loss
ambigu
storag
data
etc
furthermor
requir
certain
degre
user
train
handl
manual
step
along
similar
concept
msf
develop
smallscal
autonom
diagnost
bacteriolog
laboratori
base
appropri
feasibl
exist
adapt
techniqu
afford
cost
high
access
eas
use
may
respond
clinic
need
rtpcrisotherm
feasibl
use
robust
blood
cultur
bottl
visual
readout
new
type
media
bypass
need
blood
thu
make
easi
use
nonexpert
current
evalu
simpl
pathogen
identif
system
restrict
genu
well
antibiot
sensit
test
system
restrict
six
antibiot
use
frequent
peripher
level
also
develop
target
patient
popul
children
present
sever
ill
risk
factor
bloodstream
infect
neonat
malnourish
hiv
posit
children
fail
respond
firstlin
antibiot
treatment
hospit
war
patient
patient
trauma
prior
surgeri
provid
organismdirect
antibiot
therapi
develop
autonom
diagnost
laboratori
possibl
acquir
inform
regard
gener
question
proport
antibiot
resist
profil
key
bacteri
pathogen
therebi
provid
evidencebas
inform
antibiot
polici
appropri
prescrib
allow
improv
epidemiolog
investig
well
support
healthcar
infect
control
emerg
neglect
popul
resourcelimit
set
novel
diagnost
platform
mention
previou
section
requir
valid
target
patient
popul
well
user
requir
new
diagnost
test
even
import
pointofcar
test
often
use
nonselect
patient
exampl
patient
fever
attend
level
health
system
user
technic
background
largescal
implement
resourcelimit
countri
decid
test
also
prefer
endors
intern
donor
govern
provid
fund
unfortun
mani
pointofcar
test
launch
market
limit
laboratori
valid
use
conveni
patient
sampl
exampl
high
pathogen
load
even
cultur
pathogen
rel
high
concentr
field
evalu
perform
test
real
patient
often
harbor
low
pathogen
load
inde
often
undertaken
registr
product
due
lack
nation
intern
regulatori
mechan
applic
diagnost
test
contrast
exist
medicin
net
result
health
worker
especi
work
privat
clinic
even
patient
go
pharmaci
access
poc
test
fact
low
sensit
andor
specif
exampl
lft
chikungunya
commerci
although
sensit
maximum
field
gap
perform
measur
laboratori
field
due
sever
factor
depend
type
pathogen
technolog
use
sensit
naat
detect
bacteria
blood
compar
blood
cultur
often
disappoint
even
though
naat
abl
detect
addit
case
compar
bloodcultur
posit
blood
cultureposit
patient
bacteri
load
low
especi
adult
patient
robust
immun
explain
failur
numer
molecularbas
multiplex
platform
licens
northern
countri
aim
diagnos
rapidli
caus
sepsi
admit
patient
fig
whole
diagnost
test
develop
process
innov
valid
applic
develop
process
realiti
reiter
process
circular
linear
sourc
v
dacremont
test
work
well
blood
cultur
day
nativ
blood
impli
potenti
gain
time
essenti
patient
lost
test
base
detect
antibodi
even
igm
type
often
lack
sensit
first
day
acut
febril
episod
also
specif
antibodi
persist
sever
week
challeng
show
import
undertak
clinic
trial
real
condit
assess
first
real
perform
test
field
accuraci
best
avail
standard
impact
use
test
manag
patient
efficaci
measur
impact
health
outcom
patient
cure
rate
certain
number
day
secondari
hospit
death
sequela
done
routin
health
staff
real
work
environ
effect
measur
gener
level
complianc
test
result
guidelin
appropri
antimicrobi
prescript
fig
outcom
measur
trial
relat
health
outcom
patient
public
health
benefit
diagnosi
base
laboratori
refer
standard
diseas
anyway
suboptim
even
nonexist
treat
patient
test
result
follow
adag
even
import
nowaday
continu
increas
number
diagnost
tool
becom
avail
point
care
howev
interpret
year
malaria
microscopi
invit
disregard
test
result
treat
diseas
presumpt
base
clinic
element
low
sensit
andor
specif
adag
rather
suggest
diagnost
test
perfect
result
provid
blackorwhit
answer
rather
indic
diseas
probabl
probabl
depend
two
factor
preval
diseas
correspond
patient
popul
pretest
probabl
ii
perform
posit
neg
likelihood
ratio
test
use
diseas
rare
popul
low
pretest
probabl
even
test
reason
accuraci
posttest
probabl
posit
result
remain
low
exampl
typhoid
rapid
test
sensit
specif
thu
likelihood
ratio
lr
use
area
asia
preval
typhoid
fever
among
patient
febril
ill
posttest
probabl
calcul
use
fagan
nomogram
suggest
reason
implement
antibiot
treatment
patient
test
use
area
africa
preval
posttest
probabl
hardli
justifi
treat
patient
typhoid
rather
consid
altern
diagnos
base
principl
decis
chart
built
precis
guid
clinician
use
diagnost
test
prescrib
medicin
ration
way
paper
version
guidelin
develop
unicef
detail
strength
weak
found
literatur
guidelin
howev
deem
difficult
adopt
properli
implement
due
sever
reason
includ
long
durat
train
requir
conflict
recommend
provid
differ
guidelin
due
time
requir
harmon
updat
paper
materi
larg
scale
mobil
electron
technolog
promis
tool
overcom
challeng
electron
algorithm
inde
abl
guid
clinician
specif
branch
appli
patient
acceler
train
teach
health
worker
directli
mobil
support
even
integr
train
modul
devic
help
dissemin
quickli
health
worker
updat
version
ealgorithm
connect
fig
provid
schemat
represent
integr
tool
aim
manag
children
febril
diseas
primari
care
level
resourcelimit
countri
deriv
exist
epoct
tool
tool
integr
key
clinic
data
biosensor
measur
respiratori
rate
oxygen
satur
cardiac
rate
glycemia
hemoglobinemia
well
rapid
diagnost
test
detect
malaria
antigen
pathogen
ad
accord
local
endem
host
biomark
differenti
bacteri
viral
infect
provid
guidanc
health
worker
refer
sick
child
whether
prescrib
antimicrobi
type
medicin
also
calcul
drug
dosag
base
weight
age
beyond
scope
review
elabor
content
perform
exist
ealgorithm
platform
integr
manag
children
febril
diseas
howev
reader
refer
recent
review
publish
keitel
et
al
consult
process
data
collect
computer
decisionsupport
tool
use
clinician
sent
remot
connect
userfriendli
data
manag
system
use
surveil
outbreak
detect
document
caus
patient
fever
time
caus
potenti
epidem
decisionsupport
system
integr
result
pathogen
poc
test
reader
directli
connect
tablet
support
clinic
ealgorithm
possibl
also
remot
central
server
sourc
inform
would
patient
seen
routin
health
facil
test
poc
tool
direct
impact
case
manag
eg
malaria
typhoid
also
restrict
number
sentinel
site
addit
poc
test
aim
detect
pathogen
particular
interest
caus
larg
epidem
even
nontreat
dengu
rare
ebola
viru
diseas
would
use
data
accumul
daili
weekli
basi
depend
level
connect
avail
central
level
would
allow
health
author
conduct
realtim
diseas
surveil
weeklymonthli
report
would
also
enabl
immedi
outbreak
alarm
preset
incid
threshold
survey
diseas
reach
central
server
autom
feedback
report
also
creat
sent
clinician
tablet
discuss
supervis
visit
health
facil
train
etool
aim
improv
manag
patient
gener
particular
situat
outbreak
could
also
sent
tablet
guid
clinician
final
patient
file
support
electron
card
own
patient
could
synchron
new
consult
data
collect
clinician
tablet
fig
fulli
integr
system
seem
overoptimist
howev
compon
alreadi
proven
feasibl
challeng
find
appropri
sustain
diagnost
inform
commun
technolog
ict
platform
deploy
larg
scale
long
term
address
clinic
complex
differenti
diagnosi
episod
fever
frequent
present
syndrom
review
outlin
pointofcar
nearpati
diagnost
technolog
assist
scope
long
nonexhaust
list
describ
technolog
none
seem
satisfi
simultan
criteria
endus
need
target
product
profil
assur
criteria
regard
perform
technolog
may
fulli
autom
multiplex
prohibit
expens
costeffect
compromis
sensit
multiplex
contrast
solut
offer
multiplex
yet
benchtop
requir
laptop
electr
bare
portabl
due
size
weight
regard
technolog
describ
platform
implement
nucleic
acid
amplif
pcror
isothermalbas
almost
none
includ
parallel
immunoassay
analysi
measur
host
respons
infect
suggest
approach
equipmentfre
therefor
lack
connect
interfac
abil
howev
one
observ
common
rational
structur
describ
technolog
vast
major
base
combin
three
compon
assay
cartridg
readout
devic
sever
variat
may
exist
format
assay
cartridg
detect
principl
howev
threeelement
model
seem
backbon
describ
diagnost
platform
modular
natur
motiv
develop
manufactur
consid
semi
open
adapt
platform
address
endus
need
dynam
way
abl
quickli
modifi
panel
adapt
endem
epidem
need
review
conclud
need
electron
decis
tree
support
diagnost
tool
interact
assist
clinician
algorithm
deriv
paperbas
guidelin
computer
version
enforc
provis
output
possibl
combin
clinic
element
case
tradit
guidelin
oper
mobil
tool
tablet
receiv
input
data
sever
poc
nonpoc
diagnost
test
process
via
clinic
algorithm
provid
clinician
guidanc
regard
handl
patient
admiss
treatment
etc
interoper
ict
compon
interfac
physic
system
diagnost
test
decisionsupport
provid
solut
clinic
public
health
util
therefor
trend
expect
increas
rapidli
offer
high
impact
diagnosi
develop
countri
transform
global
healthcar
landscap
process
rather
complex
requir
knowhow
varieti
disciplin
partner
requir
multipl
interact
univers
industri
government
nongovernment
organ
well
philanthrop
institut
base
wealthi
countri
also
resourcelimit
countri
increas
chanc
make
progress
success
technolog
support
develop
motiv
partner
spirit
develop
pathway
coher
harmon
new
tool
eventu
may
implement
larg
scale
look
futur
perspect
seem
combin
technolog
nontechnolog
factor
critic
decid
whether
diagnost
poc
technolog
use
manag
patient
febril
ill
technolog
perspect
would
interest
observ
landscap
next
year
whether
labelfre
detect
technolog
transfer
laboratori
clinic
market
magnet
field
electrochem
gravimetr
eg
surfac
acoust
wave
micromechan
eg
cantilev
base
detect
technolog
laboratorymatur
fig
schemat
represent
potenti
integr
mobil
patient
manag
system
efev
central
electron
diseas
surveil
system
emerg
sourc
dacremont
candid
could
potenti
substitut
fluoresc
detect
offer
advantag
cheaper
readout
devic
regard
labelfre
technolog
import
consid
potenti
integr
sampletoansw
system
view
requir
outlin
section
addit
import
keep
track
progress
lftbase
nucleic
acid
analysi
detect
concept
rapidli
catch
combin
easi
lft
molecular
analysi
transit
laboratori
market
crucial
depend
multipl
paramet
fundament
one
sustain
scalabl
manufactur
dispos
cartridg
term
materi
process
ideal
develop
access
fabric
facil
could
perform
scaleup
manufactur
two
phase
first
prototyp
medium
scale
manufactur
thousand
ten
thousand
cartridgeschipscompon
per
year
order
serv
clinic
valid
studi
next
level
aim
larg
scale
manufactur
ten
thousand
hundr
thousand
fairli
realist
quantiti
infecti
diseas
global
impact
special
attent
given
heterogen
integr
compon
ie
system
consist
plasticsiliconglass
core
compon
integr
biolog
biochem
agent
necessari
sampletoansw
analysi
issu
stabil
compat
bio
chemic
reagent
cartridg
materi
manufactur
process
adsorpt
loss
reagent
may
prove
critic
reach
desir
limit
detect
futur
perspect
also
diagnost
tool
longer
oper
standalon
mode
broader
ecosystem
direct
integr
ict
primari
import
mean
connect
varieti
differ
tool
gener
network
exist
tradit
approach
refer
method
new
innov
tool
creat
databas
process
data
sinc
era
big
data
along
line
combin
nucleic
acid
protein
biomark
test
seem
path
reliabl
diagnosi
especi
case
syndrom
caus
sever
differ
pathogen
bacteri
viral
parasit
fungal
natur
elabor
ecosystem
approach
especi
diagnost
resourcelimit
countri
special
busi
model
develop
requir
would
render
market
target
area
attract
larg
industri
small
medium
enterpris
sme
may
choos
way
market
new
path
may
tri
market
partnership
pharmaceut
industri
obviou
diagnost
therapeut
two
side
coin
combin
interplay
healthcar
truli
progress
especi
era
antimicrobi
resist
rise
dramat
exact
issu
could
becom
bridg
unit
world
diagnost
therapeut
one
paramet
also
consid
transit
poc
technolog
laboratori
market
healthimpact
model
includ
health
econom
costimpact
analysi
one
technolog
may
compar
cheap
may
offer
ad
clinic
valu
anoth
may
seemingli
expens
may
prove
overal
cheaper
exist
test
clinic
impact
higher
developersmanufactur
compar
manufactur
cost
technolog
real
cost
test
within
healthcar
system
substitut
exist
standard
care
innov
technolog
would
welcom
lead
clinic
impact
overal
lower
price
offer
higher
clinic
impact
price
assess
novel
technolog
one
consid
actual
aim
substitut
materi
save
time
labor
save
etc
order
complet
view
cost
save
last
least
perspect
adapt
usabl
potenti
endus
whether
resourcelimit
countri
wealthi
part
world
technolog
may
block
use
even
perform
best
way
due
reason
relat
constraint
reluct
endus
behavior
chang
endus
sever
mean
eg
electron
decis
algorithm
elearn
materi
supervis
tool
key
factor
increas
accept
trust
toward
new
technolog
addit
endus
reassur
emerg
tool
aim
substitut
assist
decis
make
benefit
benefit
patient
whole
commun
